Menu

Nicole Lordi, Researcher

Nicole Lordi has worked at the Public Health Institute for over twenty years on a range of projects in the areas of survey research, evaluation, international health, and reproductive health.

Program Directors

Projects

Active Projects

California Health Interview Survey

The California Health Interview Survey (CHIS) is is the largest state health survey in the nation and is implemented by the UCLA Center for Health Policy (chis.ucla.edu) . PHI staff contribute to the development of the questionnaires, facilitate content workgroups, participate in questionnaire pre-testing, monitor interviews for data quality, analyze and write up CHIS findings and participate in the CHIS Data Access Committee.

Completed Projects

Packard Technical Assistance Project

The David and Lucile Packard Technical Assistance Project provides administrative and technical assistance to the Packard Foundation’s technical service team in India.

Organizational Development for Adolescent Sexual and Reproductive Health (ASRH) Packard Grantees

The Public Health Institute will lead an organizational strengthening initiative for Packard Foundation grantee partners in India to promote effective adaptation, mission impact, and organizational resilience during and in the wake of the COVID-19 pandemic.

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Close

Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).

More

Continue to PHI.org